


CURRICULUM VITAE

Karen J. Wiley Wernli, PhD
Kaiser Permanente Washington Health Research Institute
1730 Minor Avenue Suite 1600 ♦ Seattle, WA 98101
206.287.2934 tel ♦ 206.287.2871 fax
email: wernli.k@ghc.org ♦ @WernliKarenJ 

EDUCATION

- 1995 University of California, San Diego, California
BS Animal Physiology and Neuroscience
- 1998 University of Texas, School of Public Health, Houston, Texas
MS Epidemiology
- 2006 University of Washington, School of Public Health, Seattle Washington
PhD Epidemiology

PROFESSIONAL POSITIONS

- 1995-1996 Staff Research Associate, University of California, San Diego, La Jolla, California
- 1997-1998 Research Assistant, University of Texas, MD Anderson Cancer Center, Houston, Texas
- 1998 Comparative Health Intern, London School of Hygiene and Tropical Medicine, London, UK
- 1999-2000 Study Coordinator, University of Washington, Seattle, Washington
- 2000-2002 Project Coordinator, Fred Hutchinson Cancer Research Center, Seattle, Washington
- 2002-2006 Pre-doctoral Research Associate, Fred Hutchinson Cancer Research Center, Seattle, Washington
- 2007-2009 Post-doctoral Research Associate, Fred Hutchinson Cancer Research Center, Seattle, Washington
- 2009-2011 Research Associate II, Kaiser Permanente Washington Health Research Institute, Seattle, Washington
- 2011-2012 Research Associate III, Kaiser Permanente Washington Health Research Institute, Seattle, Washington
- 2012-2016 Assistant Investigator, Kaiser Permanente Washington Health Research Institute, Seattle, Washington
- 2012- Affiliate Assistant Investigator, University of Washington, Department of Health Services, Seattle, Washington
- 2016- Associate Scientific Investigator, Kaiser Permanente Washington Health Research Institute, Seattle, Washington

HONORS & AWARDS

- 1997-1998 Grossmont Hospital Student Scholarship

1997-1998	National Cancer Institute, Cancer Prevention Fellow Short-Term Intern
2003-2006	National Institute for Environmental Health Sciences, Environmental and Molecular Epidemiology Fellow, Pre-Doctoral Fellow
2008	Prevent Cancer Foundation and American Society of Preventive Oncology Cancer Prevention Research Fellowship
2008-2010	National Institute of Health, Loan Repayment Program Awardee
2010-2013	K12 Comparative Effectiveness Research Scholar
2011-2012	National Institute of Health, Loan Repayment Program Renewal

PROFESSIONAL DEVELOPMENT ACTIVITIES

Membership

2005-	Society for Epidemiologic Research
2007-2013	American Association for Cancer Research
2007-	American Society for Preventive Oncology
2010-	AcademyHealth
2014-	American Society for Clinical Oncology

Professional Society Activities

2008-2009	Co-Chair, American Society for Preventive Oncology, Young Investigators Workshop, "Transitioning from Mentored Scientist to Career Independence"
2012-2013	Co-Chair, American Society for Preventive Oncology, International Cancer Screening Workshop, "Undertaking Cancer Research in International Settings"

Referee

2007-	Ad hoc Reviewer, American Journal of Epidemiology
2008-	Ad hoc Reviewer, Pharmacoepidemiology and Drug Safety
2009-	Ad hoc Reviewer, Cancer Epidemiology Biomarkers and Prevention
2010-	Ad hoc Reviewer, Maturitas
2010-	Ad hoc Reviewer, Journal of Women's Health
2011-	Ad hoc Reviewer, The Lancet Oncology
2012-	Ad hoc Reviewer, Prevention Science
2012-	Ad hoc Reviewer, Annals of Epidemiology
2013-	Ad hoc Reviewer, American Journal of Radiology
2013-	Ad hoc Reviewer, American Journal of Preventive Medicine
2013-	Ad hoc Reviewer, Epidemiologic Review

2013-	Ad hoc Reviewer, Journal of Comparative Effectiveness Research
2015-	Ad hoc Reviewer, Reviews on Recent Clinical Trials
2016-	Ad hoc Reviewer, Health Services Research
2016-	Ad hoc Reviewer, JAMA Oncology
2016-	Ad hoc Reviewer, Gastroenterology
2016-	Ad hoc Reviewer, BMC Cancer

Peer-Review Study Sections

Reviewer, NIH Small Grants Program for Cancer Epidemiology, June 2012 and March 2013

Reviewer, Ministry of Health, Singapore, Singapore: September 2012 and February 2016

Reviewer, Susan G. Komen Puget Sound Chapter: February 2013

Reviewer, Maryland Health Technology Assessment: November 2013

Reviewer, Patient-Centered Outcomes Research Institute, Comparative Effectiveness Research Panel, August 2014

Reviewer, NIH Health Services Organization and Delivery Study Section, June 2016

Reviewer, Research Council of Norway, September 2016

Reviewer, NIH Health Services Organization and Delivery Study Section, June 2017

Other Committee Work

1997-1998	Student Representative, Masters of Science, University of Texas, School of Public Health
2002-2003	Member, Epidemiology Seminar Committee, University of Washington, School of Public Health
2004-2005	Member, Department Student Representative, University of Washington, School of Public Health, Department of Epidemiology
2012-2014	Lead, Clinical Prevention Research Group (CPRG), Group Health Research Institute
2013-2015	Co-Chair, Scientific Policy Committee (SPC), Group Health Research Institute
2013-	Member, Research Committee, University of Washington, Department of Health Services
2014	Member, GHRI Representative, Group Health Population Health Management Initiative
2014	Member, Faculty Search Committee, Group Health Research Institute
2016-2017	Member, American Society of Preventive Oncology, Annual Meeting Committee

BIBLIOGRAPHY

Peer-reviewed research articles

*Supervision of a student

1. Klonoff-Cohen HS, Edelstein SL, Lefkowitz ES, Srinivasan IP, Kaegi D, Chang JC, **Wiley KJ**. The effect of passive smoking and tobacco exposure through breast milk on sudden infant death syndrome. *JAMA* 1995;273(10):795-798.

2. Machevsky AM, Patel S, **Wiley KJ**, Stephenson MA, Gondo M, Brown RS, Yi ES, Benedict WF, Anton RC, Cagle PT. Artificial neural networks and logistic regression as tools for prediction of survival in patients with Stages I and II non-small cell lung cancer. *Mod Pathol* 1998;11(7):618-625.
3. Airewele GE, Sigurdson AJ, **Wiley KJ**, Frieden BE, Caldarella LW, Riccardi VM, Lewis RA, Chintagumpala MM, Ater JL, Plon SE, Bondy ML. Neoplasms in Neurofibromatosis 1 are related to gender but not to family history of cancer. *Gen Epidemiol* 2001;20:75-86.
4. **Wernli KJ**, Ray RM, Dao GL, Thomas DB, Checkoway H. Cancer among women textile workers in Shanghai, China: overall incidence patterns, 1989-1998. *Am J Ind Med.* 2003;44(6):595-9
5. Camp JE, Seixas NS, **Wernli K**, Fitzgibbons D, Astrakianakis G, Thomas DB, Gao DL, Checkoway H. Development of cancer research study in Shanghai textile industry. *Int J Occup Environ Health.* 2003;9(4):347-56.
6. De Roos AJ, Ray RM, Gao DL, **Wernli KJ**, Fitzgibbons ED, Feng Z, Astrakianakis G, Thomas DB, Checkoway H. Colorectal cancer incidence among female textile workers in Shanghai, China: A case-cohort analysis of occupational exposures. *Cancer Causes Control.* 2005;16(10):1177-1188.
7. Wong E, Ray R, Gao DL, **Wernli KJ**, Li W, Fitzgibbons ED, Feng Z, Thomas DB, Checkoway H. Reproductive history, occupational exposures and thyroid cancer risk among women textile workers in Shanghai, China. *Int Arch Occup Environ Health* 2006;79(3):251-258.
8. Chang CK, Astrakianakis G, Thomas DB, Seixas DB, Ray RM, Gao DL, **Wernli KJ**, Fitzgibbons ED, Vaughan TL, Checkoway H. Occupational exposures and risks of liver cancer among Shanghai female textile workers – A case-cohort study. *Int J Epidemiol* 2006;35(2):361-369.
9. Li W, Ray RM, Gao DL, Fitzgibbons ED, Seixas NS, Camp JE, **Wernli KJ**, Astrakianakis G, Feng Z, Thomas DB, Checkoway H. Occupational risk factors for nasopharyngeal and sinonasal cancers among female textile workers in Shanghai, China. *Occup Environ Med* 2006;63(1):39-44. PMC2078032
10. **Wernli KJ**, Fitzgibbons ED, Ray RM, Gao DL, Li W, Seixas N, Camp JE, Astrakianakis G, Feng Z, Thomas DB, Checkoway H. Occupational risk factors for esophageal and stomach cancers among women textile workers in Shanghai, China. *Am J Epidemiol* 2006;163(8):717-725.
11. Gold L, De Roos AJ, Ray RM, **Wernli KJ**, Fitzgibbons ED, Gao DL, Astrakianakis G, Thomas DB, Feng Z, Checkoway H. Brain cancer and occupational exposures in a cohort of female textile workers in Shanghai, China. *Scand J Work Environ Health* 2006;32(3):178-184.
12. Chang CK, Astrakianakis G, Thomas DB, Seixas NS, Camp JE, Ray RM, Gao DL, **Wernli KJ**, Li W, Fitzgibbons ED, Vaughan T, Checkoway H. Risks of biliary tract cancer and occupational exposures among Shanghai women textile workers: a case-cohort study. *Am J Ind Med* 2006;49(8):690-8.
13. **Wernli KJ**, Ray RM, Gao DL, De Roos AJ, Thomas DB, Checkoway H. Reproductive risk factors and endometrial cancer. *Cancer Causes Control* 2006;17(7):949-55.
14. **Wernli KJ**, Astrakianakis G, Camp J, Ray RM, Chang CK, Li GD, Thomas DB, Checkoway H, Seixas N. Development of a job exposure matrix (JEM) for the textile industry in Shanghai, China. *J Occup Environ Hyg* 2006;3(10):521-9.
15. Li W, Ray RM, Gao DL, Fitzgibbons ED, Seixas NS, Camp JE, **Wernli KJ**, Astrakianakis G, Feng Z, Thomas DB, Checkoway H. Occupational risk factors for pancreatic cancer among female textile workers in Shanghai, China. *Occup Environ Med* 2006;63(12):788-93. PMC2078009
16. Rosenblatt KR, Gao DL, Ray RM, Rowland MR, Nelson ZC, **Wernli KJ**, Li W, Thomas DB. Induced abortions and the risk of all cancers combined and site-specific cancers in Shanghai. *Cancer Causes Control* 2006;17(10):1275-1280.
17. Astrakianakis G, Seixas NS, Ray R, Camp JE, Gao DL, Feng Z, Li W, **Wernli KJ**, Fitzgibbons ED, Thomas DB, Checkoway H. Lung cancer risks among female textile workers exposed to endotoxin. *J Natl Cancer Inst* 2007;99(5):357-64.

18. Ray RM, Gao DL, Li W, **Wernli KJ**, Astrakianakis G, Seixas NS, Camp JE, Fitzgibbons ED, Feng Z, Thomas DB, Checkoway H. Occupational exposures and breast cancer among textile workers in Shanghai. *Epidemiol* 2007;18(3):383-392.
19. Rosenblatt KR, Gao DL, Ray RM, Nelson ZC, **Wernli KJ**, Li W, Thomas DB. Monthly injectable contraceptives and risk of all cancer combined and site-specific cancers in Shanghai. *Contraception* 2007;76(1):40-44.
20. **Wernli KJ**, Ray RM, Gao DL, Fitzgibbons ED, Camp JE, Astrakianakis G, Seixas N, Wong EY, Li W, De Roos AJ, Feng Z, Thomas DB, Checkoway H. Ovarian cancer in association with occupational risk factors among women textile workers in Shanghai, China. *Epidemiol* 2008;19(2):244-250.
21. **Wernli KJ**, Newcomb PA, Hampton J, Trentham-Dietz A, Egan KM. Hormone therapy and ovarian cancer: incidence and survival. *Cancer Causes Control* 2008;19(6):605-613. PMC2729759
22. **Wernli KJ**, Newcomb PA, Hampton J, Trentham-Dietz A, Egan KM. Inverse association of NSAID use and ovarian cancer in relation to oral contraceptive use and parity. *Br J Cancer* 2008;98(11):1781-1783. PMC2410126
23. **Wernli KJ**, Ray RM, Gao DL, , Fitzgibbons ED, Camp JE, Astrakianakis G, Seixas N, Li W, De Roos AJ, Feng Z, Thomas DB, Checkoway H. Occupational risk factors for endometrial cancer among women textile workers in Shanghai, China. *Am J Ind Med* 2008;51(9):673-679. PMC2574926
24. Rosenblatt KR, Gao DL, Ray RM, Nelson ZC, **Wernli KJ**, Li W, Thomas DB. Oral contraceptives and risk of all cancers combined and site-specific cancers in Shanghai, China. *Cancer Causes Control* 2009;20(1):27-34. PMC2628413
25. Wong EY, Ray RM, Gao DL, **Wernli KJ**, Li W, Fitzgibbons ED, Camp JE, Astrakianakis G, Seixas N, Heagerty P, Thomas DB, Checkoway H. Dust and chemical exposures and spontaneous abortion risk among textile workers in Shanghai, China. *Occup Environ Med* 2009;66(3):161-168. PMC2862777
26. **Wernli KJ**, Hampton JM, Trentham-Dietz A, Newcomb PA. Antidepressant medication use and breast cancer risk. *Pharmacoepidemiol Drug Saf* 2009;18(4):284-290. PMC2720762
27. Shadman M, Newcomb PA, Hampton JM, **Wernli KJ**, Trentham-Dietz A. Non-steroidal anti-inflammatory drugs and statins in relation to colorectal cancer risk. *World J Gastroenterol* 2009;15(9):2336-2339. PMC2684598
28. **Wernli KJ**, Wang Y, Zheng Y, Potter JD, Newcomb PA. Differences in gravidity and parity: the association with colorectal cancer risk. *J Women's Health* 2009; 18(7):995-1001. PMC2851134
29. Wong EY, Ray RM, Gao DL, **Wernli KJ**, Li W, Fitzgibbons ED, Camp JE, Heagerty P, Thomas DB, Checkoway H. Physical activity, physical exertion, and spontaneous abortion risk in women textile workers in Shanghai, China. *Am J Ind Med* 2010;53(5):497-505. PMC2863132
30. Braithwaite D, **Wernli KJ**, Anton-Culver H, Engstrom P, Greenberg ER, Meyskens F. Opportunities for cancer epidemiology and control in low- and middle-income countries: a report from the american society for preventive oncology international cancer prevention interest group. *Cancer Epidemiol Biomarkers Prev.* 2010 Jul;19(7):1665-7.
31. **Wernli KJ**, Newcomb PA, Wang Y, Makar KW, Shadman M, Chia VM, Burnett-Hartman A, Wurscher MA, Zheng Y, Mandelson MT. Body size, IGF and growth hormone polymorphisms, and premalignant colorectal lesions. *Growth Horm IGF Res* 2010;20(4):305-309. PMC2918710
32. **Wernli KJ**, Newcomb PA, Hampton JM, Trentham-Dietz A. Use of antidepressants and NSAIDs in relation to mortality in long-term breast cancer survivors. *Pharmacoepidemiol Drug Saf* 2011;29(2):131-137. PMC3074001
33. Checkoway H, Ray RM, Lundin JI, Astrakianakis G, Seixas NS, Camp JE, **Wernli KJ**, Fitzgibbons ED, Li W, Feng Z, Gao DL, Thomas DB. Lung cancer and occupational exposures other than cotton dust and endotoxin among women textile workers in Shanghai, China. *Occup Environ Med* 2011;68(6):425-429. PMC3071898

34. **Wernli KJ**, Bowles EJ, Haneuse S, Elmore JG, Buist DSM. Timing of follow-up after abnormal screening and diagnostic mammograms. *Am J Managed Care* 2011;17(2):162-167. PMC3151253
35. Coghill AE, Newcomb PA, Chia VM, Zheng Y, **Wernli KJ**, Passarelli MN, Potter JD. Pre-diagnostic NSAID but not hormone therapy use is associated with survival after a diagnosis of colorectal cancer in women. *Br J Cancer* 2011;104(6):763-768. PMC3048198
36. Burnett-Hartman A N, Newcomb PA, Mandelson MT, Adams SV, **Wernli KJ**, Wang Y, Shadman M, Wurscher M, Makar K. Colorectal polyp type and the association with smoking, charred meat intake, and microsomal epoxide hydrolase polymorphisms. *Nutr Cancer* 2011;63(4):583-592. PMC3145495
37. Schur E, Elmore J, Onega T, **Wernli KJ**, Sickles E, Haneuse S. The impact of obesity on follow-up after an abnormal screening mammogram. *Cancer Epidemiol Biomark Prev* 2012;21(2):327-336. PMC3275693
38. Passarelli MN, Phipps AI, Potter JD, Makar KW, Coghill AE, **Wernli KJ**, White E, Chan AT, Hutter CM, Petters U. Common single nucleotide polymorphisms in the 5' promoter region of estrogen receptor β are associated with colorectal cancer survival in postmenopausal women. *Cancer Res* 2013;73(2):767-775. PMC3588850
39. Braithwaite D, Zhu W, Hubbard RA, O'Meara ES, Miglioretti DL, Geller B, Dittus K, Moore D, **Wernli KJ**, Mandelblatt J, Kerlikowske K. Screening outcomes in older US women undergoing multiple mammograms in community practice: does interval, age or comorbidity score after tumor characteristics or false positive rates? *J Natl Cancer Inst* 2013;105(5):334-341. PMC3589257
40. **Wernli KJ**, Rutter CM, Dachmann A, Zafar H. Suspected extracolonic neoplasms detected on CT colonography: literature review and possible outcomes. *Acad Radiol.* 2013 June; 20(6): 667-674.. PMC3654044
41. Kerlikowske K, Zhu WW, Hubbard R, Gellar B, Dittus K, Braithwaite D, O'Meara E, **Wernli KJ**, Miglioretti D, for the Breast Cancer Surveillance Consortium. Breast cancer risk by breast density, menopause, and post-menopausal hormone therapy use. *JAMA Intern Med* 2013;173(9):807-816. PMC3699693
42. **Wernli KJ**, Kitahara CM, Tamers SL, Al-Temimi MH, Braithwaite D. Undertaking cancer research in international settings: report from the American Society for Preventive Oncology special interest group on international issues in cancer. *Cancer Epidemiol Biomarkers Prev* 2013;22(9):1638-1641. PMC3919027
43. Li W, Ray RM, Thomas DB, Yost MY, Breslow N, Gao DL, Fitzgibbons ED, Camp JE, Wong EY, **Wernli KJ**, Checkoway H, Davis S. Occupational exposure to magnetic fields and breast cancer among women textile workers in Shanghai, China. *Am J Epidemiol* 2013;178(7):1038-1045. PMC3783098
44. O'Meara ES, Zhu W, Hubbard R, Braithwaite D, Kerlikowske K, Dittus K, Gellar B, **Wernli KJ**, Miglioretti M. Mammography screening interval in relation to tumor characteristics and false-positive risk by race/ethnicity and age. *Cancer* 2013;119(22):3959-3967. PMC3935985
45. **Wernli KJ**, DeMartini WB, Ichikawa L, Lehman C, Onega TL, Kerlikowske K, Gellar BM, Hofmann M, Yankaskas BC. Patterns of breast magnetic resonance imaging use in community practice. *JAMA Intern Med* 2014;174(1):125-132. PMC3905972
46. **Wernli KJ**, O'Meara E, Kerlikowske K, Miglioretti D, Muller CY, Onega T, Sprague B, Henderson L, Buist DSM. Investigation of mammographic breast density as a risk factor for ovarian cancer. *J Nat Cancer Instit* 2014;106(1):djt341. PMC3906993
47. *Cohen-Cline H, **Wernli KJ**, Bradford SC, Boles-Hall M, Grossman D. Use of interactive voice response and colorectal cancer screening. *Med Care* 2014;52(6):496-499. PMID: 24638119
48. Aiello Bowles EJ, **Wernli KJ**, Gray HJ, Bogart A, Delate T, O'Keefe-Rosetti M, Nekhylyudov L, Trice Loggers E. Diffusion of intraperitoneal chemotherapy in women with advanced ovarian cancer in

community settings 2003-2008: the effect of the NCI clinical recommendation. *Front Oncol* 2014;4:43. PMC3948091

49. Johnson K, Kamineni A, Fuller S, Olmstead D, **Wernli KJ**. How the provenance of electronic health record data matters for research: a case example using system mapping. *eGEMs* 2014;2(1):4. PMC4371416
50. **Wernli KJ**, Hubbard R, Johnson E, Chubak J, Kamineni A, Rutter CM. Patterns of colorectal cancer screening uptake in men and women newly-eligible for screening. *Cancer Epidem Biomarker Prev* 2014;23(7): 1230-1237. PMC4082473
51. Tiro JA, Kamineni A, Levin TR, Schottinger JE, Zhen Y, Chubak J, Corley D, Doubeni C, Gupta S, Halm E, Skinner CS, Rutter C, **Wernli KJ**, Klabunde CN. A conceptual model for the Population-based Research Optimizing Screening through Personalized Regimens (PROSPR) Consortium. *Cancer Epidem Biomarker Prev* 2014;23(7): 1147-1158. PMC4148641
52. Lee CI, Ichikawa L, Rochelle MC, Kerlikowske K, Miglioretti DL, Sprague BL, DeMartini WB, **Wernli KJ**, Joe BN, Yankaskas BC, Lehman CD. Breast MRI BI-RADS assessments and abnormal interpretation rates by clinical indication in US community practices. 2014 Nov;21(11):1370-6. PMC4194166
53. Onega T, Weiss JL, Kerlikowske K, **Wernli K**, Buist DSM, Henderson LM, Goodrich ME, Alford-Teaster JA, Virnig B, Tosteson ANA, DeMartini W, Hubbard R. The influence of race/ethnicity and place of service on breast reconstruction for Medicare beneficiaries with mastectomy. Springerplus. 2014 Aug 8;3:416. doi: 10.1186/2193-1801-3-416. eCollection 2014. PMC4137047
54. Li W, Ray RM, Thomas DB, Davis S, Yost M, Breslow N, Gao DL, Fitzgibbons ED, Camp JE, Wong E, **Wernli KJ**, Checkoway H. Shift work and breast cancer among women textile workers in Shanghai, China. *Cancer Causes Control* 2015;26(1):143-150. PMC4323154
55. Gallagher LG, Li W, Ray RM, Romano ME, **Wernli KJ**, Gao DL, Thomas DB, Checkoway H. Occupational exposures and risk of stomach and esophageal cancers: update of a cohort of female textile workers in Shanghai, China. *Am J Ind Med* 2015;58(3):267-275. PMID: 25611949
56. Kerlikowske K, Zhu W, Tosteson AN, Sprague BL, Tice JA, Lehman CD, Miglioretti DL; Breast Cancer Surveillance Consortium. Identifying women with dense breasts at high risk for interval cancer: a cohort study. *Ann Intern Med* 2015;162(10):673-681.
57. Wieneke AE, Bowles EJA, Cronkite D, **Wernli KJ**, Gao H, Carrell D, Buist DSM. Validation of natural language processing to extract breast pathology procedures and results. *J Pathol Inform* 2015; 1:38.
58. Henderson LM, Miglioretti DL, Kerlikowske K, **Wernli KJ**, Sprague BL, Lehman CM. Breast cancer characteristics associated with digital versus film-screen mammography for screen-detected and interval cancers. *AJR Am J Roentgenol* 2015;205(3):676-684.
59. Lee AY, Ichikawa L, Lee JM, Lee CI, DeMartini WB, Joe BN, **Wernli KJ**, Sprague BL, Herschorn SD, Lehman CD. Concordance of BI-RADS assessments and management recommendations for breast MRI in community practice. *Am J Radiol* 2016;206(1):211-216
60. Miglioretti DL, Zhu W, Kerlikowske K, Sprague BL, Onega T, Buist DS, Henderson LM, Smith RA, Breast Cancer Surveillance Consortium. Breast tumor prognostic characteristics and biennial vs annual mammography, age, and menopausal status. *JAMA Oncol* 2015;1(8):1069-77.
61. Haas J, Hill D, Wellman R, Hubbard RA, Lee CI, **Wernli KJ**, Stout N, Tosteson A, Henderson LM, Alford-Teaster J, Onega T. Disparities in the use of screening magnetic resonance imaging of the breast in community practice by race, ethnicity, and socioeconomic status. *Cancer* 2016;122(4):611-617.
62. Johnson D,* Bush M,* Brandzel S, **Wernli KJ**. The patient voice in research; evolution of a role. *Res Involvement and Engagement* 2016;2:6.
63. Onega T, Tosteson ANA, Weiss JA, Alford-Teaster J, Hubbard RA, Henderson LM, Kerlikowske K, Goodrich ME, Donoghue C, **Wernli KJ**, DeMartini WB, Virnig BA. Costs of diagnostic and

preoperative workup with and without breast MRI in older women with a breast cancer diagnosis. *BMC Health Serv Res* 2016;16(1):76.

64. **Wernli KJ**, Brenner AT, Rutter C, Inadomi J. Short-term risks associated with general anesthesia during colonoscopy compared to conscious sedation in US adult population. *Gastroenterology* 2016;150(4):888-894.
65. Onega T, Weiss JE, Buist DS, Tosteson AN, Henderson LM, Kerlikowske K, Goodrich ME, O'Donoghue C, **Wernli KJ**, DeMartini WB, Virning BA, Bennette CS, Hubbard RA. Breast MRI in the diagnostic and preoperative workup among Medicare beneficiaries with breast cancer. *Med Care* 2016;54(7):719-724.
66. Hubbard RA, O'Meara ES, Henderson LM, Hill D, Braithwaite D, Haas JS, Lee CI, Sprague BL, Alford-Teaster J, Tosteson A, **Wernli KJ**, Onega T. Multilevel factors associated with long-term adherence to screening mammography in older women in the US. *Prev Med* 2016;89:169-177.
67. **Wernli KJ**, Henrikson NB, Morrison CC, Nguyen M, Pocobelli G, Whitlock E. Skin Cancer in Adults: Screening. Evidence Report/Technology Assessment No. 14-05210-EF-1(Prepared by Kaiser Permanente Research Affiliates Evidence-based Practice Center under Contract No. HHS A290201200015i) Rockville, MD: Agency for Healthcare Research and Quality; 2016.
68. **Wernli KJ**, Henrikson NB, Morrison CC, Nguyen M, Pocobelli G, Blasi PR. Screening for skin cancer in adults: Updated evidence report and systematic review for the US Preventive Services Task Force. *JAMA* 2016;316(4):436-447.
69. Shortreed SM, Johnson E, Rutter CM, Kamineni A, **Wernli KJ**, Chubak J. Cohort restriction based on prior enrollment: examining potential biases in estimating cancer and mortality risk. *Obs Stud* 2016;2;51-64.
70. Brandzel S, Rosenberg DE, Johnson D, Bush M, Kerlikowske K, Onega t, Henderson L, Nekhlyudov L, Buist D, DeMartini W, **Wernli KJ**. A qualitative analysis of women's experiences and preferences regarding breast imaging after breast cancer treatment. *Patient Preference and Adherence* 2017;11 199–204.
71. Carter-Harris L, Brandzel S, **Wernli KJ**, Roth J, Buist D. A qualitative study exploring why individuals opt out of lung cancer screening. *Fam Pract* 2017;34(2):239-244.
72. **Wernli KJ**, Arao RF, Hubbard RA, Sprague B, Alford-Teaster J, Haas J, Henderson L, Hill D, Lee C, Tosteson A, Onega T. How have breast cancer screening intervals changed since the 2009 USPSTF guideline update? *J Women's Health*, 2017;26(8):820-827.
73. Knerr S, **Wernli KJ**, Leppig K, Ehrlich K, Graham AL, Farrell D, Evans C, Luta G, Schwartz MD, O'Neill SC. A web-based personalized risk communication and decision-making tool for women with dense breasts: design and methods of a randomized controlled trial within an integrated health care system. *Contemp Clin Trials* 2017;56:25-33.
74. Balasubramanian BA, Garcia MP, Corley DA, Doubeni CA, Haas JS, Kameneni A, Quinn VP, **Wernli K**, Zheng Y, Skinner CS. Racial/ethnic differences in obesity and comorbidities between safety-net and non-safety integrated health systems. *Medicine (Baltimore)* 2017;96(11):e6326.
75. Sethi RK, Buchlak QD, Yanamadala V, Anderson ML, Baldwin EA, Mecklenburg RS, Leveque JC, Edwards AM, Shea M, Ross L, **Wernli KJ**. A systematic multidisciplinary initiative reduces risk of complications in adult scoliosis surgery. *J Neurosurg Spine* 2017;26(6):744-750.
76. Lee JM, Ichikawa L, Valencia E, Miglioretti DL, **Wernli K**, Buist DSM, Kerlikowske K, Henderson LM, Sprague BL, Onega T, Rauscher GH, Lehman CD. Performance Benchmarks for Screening Breast MRI in Community Practice. *Radiology* 2017;285(1):44-52.
77. Hubbard RA, Johnson E, Chubak J, **Wernli KJ**, Kamineni A, Bogart A, Rutter C. Estimating screening test effectiveness when screening indication is unknown using generalized linear finite mixture models. *Health Serv Outcomes Res Methodol* 2017 17(2):101-112.

78. Miles R, Wan F, Onega TL, Lenderink-Carpenter A, O'Meara ES, Zhu W, Henderson LM, Haas JS, Hill DA, Tosteson ANA, **Wernli KJ**, Alford-Teaster J, Lee JM, Lehman CD, Lee CI. Availability of On-Site Supplemental MRI Screening and Factors Associated with Use Among Patients at Elevated Breast Cancer Risk. In press, *J Women's Health*.
79. Sakoda LC, Henderson LM, Caverly TJ, **Wernli KJ**, Katki HA. Applying risk prediction models to optimize lung cancer screening: Current knowledge, challenges, and future directions. *Curr Epidemiol Rep* epub 2017.

Non-refereed publications

1. Astrakianakis G, Seixas NS, Ray RM, Camp JE, Gao DL, Feng Z, Li W, **Wernli KJ**, Fitzgibbons ED, Thomas DB, Checkoway H. Re: Lung cancer risk among female textile workers exposed to endotoxin. *J Natl Cancer Inst* 2010;102(12):1-2.
2. Braithwaite D, **Wernli KJ**, Anton-Culver H, Engstrom P, Greenberg ER, Meyskens F. Opportunities for cancer epidemiology and control in low- and middle-income countries: A report from the ASPO International Cancer Prevention Interest Group. *Cancer Epidemiol Biomarkers Prev* 2010;19(7):1665-1667.
3. Carlos RC, Buist DS, **Wernli KJ**, Swan JS. Patient-centered outcomes in imaging: quantifying value. *J Am Coll Radiology* 2012;9(10);725-728. PMC3810945
4. **Wernli KJ**, Inadomi JM. Anesthesia for colonoscopy: too much of a good thing? *JAMA Intern Med* 2013;173(9):807-816.
5. **Wernli KJ**, Brenner A, Rutter CM, Inadomi JM. Response to sedation and colonoscopy. *Gastroenterology* 2016;151(3):564
6. Lavalley DC, Gore JL, Lawrence SO, Lindsay J, Marsh S, Scott MR, **Wernli K**. Initiative to Support Patient Involvement in Research (INSPIRE): Findings from Phase I Interviews [Internet]. September 2016. Available from: <http://www.becertain.org/projects/patient-engagement>
7. Lavalley DC, Gore JL, Lawrence SO, Lindsay J, Marsh S, Scott MR, **Wernli K**. Initiative to Support Patient Involvement in Research (INSPIRE): Community Workshop Report [Internet]. October 2016. Available from: <http://www.becertain.org/projects/patient-engagement>

Published abstracts

1. **Wernli K**, Hubbard R, Johnson E, Chubak J, Kamineni A, Rutter C. A2-1: Patterns of colorectal cancer testing in men and women newly eligible screening. *Clin Med Res* 2013;11(3):123.
2. **Wernli KJ**, Arao RF, Hubbard RA, Sprague B, Alford-Teaster J, Haas J, Henderson L, Hill D, Lee C, Tosteson A, Onega T. How have breast cancer screening intervals changed since the 2009 USPSTF guideline update? *Cancer Epidemiol Biomark Prev* 2016;25:558

Under Review/In Preparation

1. Greene SM, Brandzel S, **Wernli KJ**. Principles of patient engagement. Submitted to the *Permanente Journal*.
2. **Wernli KJ**, Brandzel SD, Buist DSM, Bush M, DeMartini W, Ichikawa L, Haas C, Henderson LM, Johnson D, Kerlikowske K, McColgin D, Miglioretti CL, Nekhlyudov L, Onega T, Rosenberg DE. Comparative effectiveness of surveillance imaging modalities in breast cancer survivors. Revise and resubmit Draft Final research report to Patient Centered Outcomes Research Institute.
3. **Wernli KJ**, Ichikawa L, Kerlikowske K, Buist DSM, DeMartini W, Brandzel SD, Bush M, Johnson D, Henderson LM, Nekhlyudov L, Onega T, Sprague B, Lee J, Lehman C, Miglioretti D. Performance characteristics of surveillance breast MRI compared with mammography in women after treatment for primary breast cancer. Revise and resubmit to *J Clin Oncol*.

4. Haas C,* Nekhlyudov L, Bush M, Johnson D, Gleason T, Javid S, Kaufman C, Lee J, Sneeringer R, Specht J, Stitham S, **Wernli KJ**. Surveillance for second breast cancer events in women with a personal history of breast cancer using breast MRI: a systematic review. Submitted to JAMA Oncology.
5. **Wernli KJ**, Kamineneni A, Johnson E, Shortreed S, Green BB, Rutter CM, Chubak J. Current patterns of colorectal cancer screening in US insured population. In preparation for Prev Med.
6. Haas C,* Phipps A, Hajat A, Kamenini A, Chubak J **Wernli KJ**. Disparities in completion of fecal immunochemical tests for colorectal cancer screening in a health maintenance organization setting. In preparation for Cancer Epidem Biomark Prev.

Book Chapters

1. Newcomb PA, **Wernli KJ**. Risk Factors. In Breast Cancer: Risk Reduction and Early Detection Strategies. Edited by E. Sauter and M. Daly. Springer. New York City, 2010, pages 3-22.
2. **Wernli KJ**, Inadomi J. Sedation issues in colonoscopy: quality and economic considerations. In Colorectal Cancer Screening. Edited by J. Allen and S. Haukat. Springer. New York City, 2015, 141-151.
3. Bowles EA, **Wernli KJ**. Breast cancer screening: evidence and recommendations. In Rotation in Radiology. Edited by C. Lehman, C. Lee, and L. Bassett. In press.

FUNDING HISTORY

Completed Research Funding (as Principal Investigator or Co-Investigator)

1. Research Fellow. Environmental and Molecular Epidemiology Training Grant. 5T32ES007262-13 National Institute of Environmental Health Sciences Training Award (Principal Investigator: Harvey Checkoway). 2003-2006. Effort: 100%.
2. Principal Investigator: Medications, multivitamins, and breast cancer survival. Prevent Cancer Foundation Fellow (Post-doctoral Fellowship Award). 2008-2010. Direct costs: \$80,000; Effort: 50%. *Aim: to assess medication use and cancer survival in breast cancer survivors.*
3. Principal Investigator: Interactive voice response and colorectal cancer screening. Group Health Research Institute Development Fund. 2012. Direct costs: \$37,882. Effort: 5%. *Aim: To compare the effectiveness of IVR to usual care on colorectal cancer screening rates to increase adherence at 3, 6, 9 and 12 months after the intervention.*
4. Scholar (Site PI): Comparative Effectiveness Research Scholar. K12HS019482 Career Development Award funded by Agency for Healthcare Research and Quality. 2010-2013. Direct Costs: \$206,797. Effort: 80%. *Aim: A mentored Comparative Effectiveness Research Training Program (K12) at the University of Washington that will equip Scholars with the skills to plan, conduct, and apply practical clinical and health services research.*
5. Principal Investigator: Mammographic breast density and ovarian cancer. R03 CA159080 funded by National Cancer Institute. 2011-2014. Direct costs: \$100,000. Effort: 10%. *Aim: To estimate the association between mammographic breast density and incident ovarian cancer risk among women aged 40-79 years who participated in the Breast Cancer Surveillance Consortium during 1996-2008; and to determine if the association between mammographic breast density and incident ovarian cancer risk is modified by ovarian cancer risk factors, including parity, hormone therapy use, oral contraceptive use, family history of breast or ovarian cancer, and menopausal status.*
6. Principal Investigator. Complication rates from complex spine surgery. Group Health Research Institute Development Fund. 2013-2014. Direct costs: \$98,000. Effort: 10%. *Aim: To evaluate 30 day and one year complication rates in complex spine patients from 2008-2012.*

7. Co-Investigator. Risk-based cancer screening in community settings. P01CA149365 funded by National Cancer Institute (Principal Investigators: Diana Miglioretti and Karla Kerlikowske). 2011-2016. Direct costs: \$23,965,000. Effort: 5%. *Aim: Project 3, Community-based Utilization of Breast Imaging Technologies, will assess risk-based screening in diverse populations and identify disparities in access and use of new technologies.*
8. Co-Investigator. Effectiveness of pre-operative MRI in breast cancer surgery and outcomes. R01 CA149365 funded by National Cancer Institute (Principal Investigator: Tracy Onega). 2012-2016. Direct costs: \$695,000. Effort: 5%. *Aim: 1) examine the influence of preoperative breast MRI on additional cancer detection, preoperative work-ups and the relation with mastectomy vs. breast conserving surgery; 2) compare breast MRI with mammography plus ultrasound in relation to re-excision, subsequent tumor events, and mortality; 3) assess utilization of preoperative breast MRI nationally and in subgroups of women, such as those with increased breast cancer risk; 4) estimate population-wide impacts of preoperative breast MRI use through Markov models of utilization and outcomes.*
9. Co-Investigator. Systematic Evidence Reviews to Support the U.S. Preventive Services. Task Force (USPSTF). Agency for Healthcare Research and Quality. (Principal Investigator: Evelyn Whitlock) 2014-2016. Direct Costs: \$233,517. Effort: 20%. *Aim: To complete systematic evidence review for skin cancer screening.*
10. Co-Lead. Lung cancer screening registry. Group Health Research Institute Development Fund. 2015-2016. Direct costs: \$60,000. Effort: 5%. *Aim: To build Group Health infrastructure on the conduct of lung cancer screening.*
11. Site PI. The Clare Project 2016. Group Health Research Institute Development Fund. 2016. Direct costs: \$54,000. Effort: 5%. *Aim: To understand patient, caregiver and provider perspectives in the clinical decision making for AYA patients with advanced cancer in Cohort 2.*
12. Site PI. K12 Mentor awards. K12 HS022982 funded by Agency for Healthcare Research and Quality. 2015-2016. GH Direct Costs: \$10,000. Effort: 2%. *Aim: To support to senior mentors for K12 Scholars in patient-centered outcomes research.*
13. Co-Investigator and Site PI. Patient Voices: Supporting Patient Involvement in the Learning Health Care System. Eugene Washington Patient Engagement Award funded by Patient Centered Outcomes Research Institute. (Principal Investigator: Danielle Lavalley) 2015-2017. Direct Costs: \$16,386. Effort: 5%. *Aim: To establish training, provide tools, and create a network to help researchers and patients better connect and collaborate in patient-centered outcomes research.*
14. Site PI. K12 Mentor awards. K12 HS022982 funded by Agency for Healthcare Research and Quality. 2016-2017. Direct Costs: \$15,000. Effort: 2%. *Aim: To support to senior mentors for K12 Scholars in patient-centered outcomes research in Cohort 3.*

Current Research Funding (as Principal Investigator or Co-Investigator)

1. Co-Investigator and Project Lead. Studying colorectal cancer: effectiveness of screening strategies (SuCESS). U54 CA163261 funded by National Cancer Institute (Principal Investigator: Jessica Chubak). 2011-2017. Direct Costs: \$4,705,276. Effort: 15-25%. *Aim: "Comparative effectiveness of colorectal cancer screening as practiced," will provide information about how screening is practiced, about patient decisions regarding screening modalities, and about the comparative effectiveness of different screening regimens as practiced.*
2. Principal Investigator. Comparative effectiveness of surveillance imaging strategies in breast cancer. CE-1304-6656 funded by Patient Centered Outcomes Research Institute. 2013-2017. Direct costs: \$1,346,619. Effort: 40%. *Aim: To compare mammography to MRI using data from the Breast Cancer Surveillance Consortium—the largest collection of breast cancer surveillance data in the nation and will use data from more than 36,000 women diagnosed with breast cancer between 2005 and 2012 to determine how well each test works.*

3. Co-Investigator and Site PI. Applying breast density to risk counseling. R01CA190221 funded by National Cancer Institute (Principal Investigator: Suzanne O'Neill). 2015-2019. Direct Costs: \$701,283. Effort: 15% *Aim: To implement and evaluate a web-based interactive intervention vs. usual care among members of Group Health (aged 40-69) whose high breast density and other risk factors place them at high 5-year (>1.66 percent) or lifetime (>20 percent) risk for breast cancer.*
4. Principal Investigator. National trends in end of life care for adolescent and young adult cancer patients. R21CA205309 funded by National Cancer Institute. 2016-2018. Direct Costs: \$275,000. Effort: 15%. *Aim: To describe and compare the receipt of medical, surgical, and pharmacologic interventions in AYA population within the last 30 days and 365 days of life by evaluating temporal trends from 2003 to 2015 and U.S. geographic variation.*
5. Co-Investigator and Patient Engagement Core Lead. Comparative effectiveness of breast cancer screening, diagnosis and management in community practice. Submitted to the Patient Centered Outcomes Research Institute (Principal Investigators: Karla Kerlikowske, Diana Miglioretti, Tracy Onega, Anna Tosteson). 2016-2021. Direct Costs: \$3,831,993. Effort: 15%. *Aim: To evaluate breast imaging effectiveness by breast density to screen for breast cancer and diagnosis evaluation for newly diagnosed breast cancer.*
6. Co-Investigator. Advanced breast imaging: trends and outcomes associated with recent breast density reporting legislation. Submitted to the National Cancer Institute (Principal Investigator: Natasha Stout). 2017-2022. Direct costs: \$132,397. Effort: 15%
7. Co-Investigator. BCSC P01 Submitted to the National Cancer Institute (Principal Investigator: Diana Miglioretti). 2017-2022. Direct costs: \$955,914 Effort 10%. To evaluate breast cancer screening in community practice in US.

Pending Research Funding (as Principal Investigator or Co-Investigator)

1. Principal Investigator and Site PI. Lung cancer screening in community health practices (LUCID). Submitted to Patient Centered Outcomes Research Program. Direct Costs: \$11,688,837. Effort 40%. *Aim: To develop patient-centered lung cancer screening by evaluating risk prediction and shared decision making.*

CONFERENCES & SYMPOSIUMS

Contributed oral presentations

1. **Wernli KJ**, Ray RM, Dao GL, Thomas DB, Checkoway H. Cancer incidence in a cohort of female textile workers in Shanghai, China. International EPICOH Congress of Epidemiology in Occupational Health, Barcelona, Spain, September 2002.
2. **Wernli KJ**. Use of MRI in breast cancer surveillance. The beginning of a comparative effectiveness research study. National Research Service Award, Seattle, WA, June 2011.
3. **Wernli KJ**, Hubbard R, Johnson E, Chubak J, Kamineni A, Rutter CM. Patterns of colorectal cancer screening uptake in men and women newly-eligible for screening. American Society for Preventive Oncology, Memphis, TN, March 2013.
4. **Wernli KJ**, Hubbard R, Johnson E, Chubak J, Kamineni A, Rutter CM. Patterns of colorectal cancer screening uptake in men and women newly-eligible for screening. HMO Research Network, San Francisco, CA, April 2013.
5. **Wernli KJ**, Arao RF, Hubbard RA, Sprague B, Alford-Teaster J, Haas J, Henderson L, Hill D, Lee C, Tosteson A, Onega T. How have breast cancer screening intervals changed since the 2009 USPSTF guideline update? American Society for Preventive Oncology, Columbus, OH, March 2016.

Selected contributed poster presentations

1. Hutter CM, **Wernli KJ**, Wong EY. Adverse pregnancy and birth outcomes in relation to psychosocial job strain. Washington State Public Health Association, Yakima, WA, October 2003.
2. **Wernli KJ**, Ray RM, Gao DL, Seixas N, De Roos AJ, Thomas DB, Checkoway J. Occupational risk factors for endometrial and ovarian cancers among textile workers in Shanghai, China. Society for Epidemiologic Research, Toronto, Canada, June 2005.
3. **Wernli KJ**, Newcomb PA, Trentham-Dietz A, Hampton JM, Wong EY, Egan KM. Types and Patterns of Postmenopausal Hormone Use and Ovarian Cancer. American Society for Preventive Oncology, Houston, TX, March 2007
4. **Wernli KJ**, Newcomb PA, Hampton JM, Trentham-Dietz A, Egan KM. Parity modifies the relationship between NSAIDs and ovarian cancer. American Association for Cancer Research, Frontiers in Cancer Prevention, Philadelphia, PA, December 2007.
5. **Wernli KJ**, Wang Y, Makar KW, Burnett-Hartman A, Shadman M, Zheng Y, Mandelson M, Newcomb PA. Body size, IGF and growth hormone polymorphisms, and premalignant colorectal lesions in men and women. Society for Epidemiologic Research, Anaheim, CA, June 2009.
6. **Wernli KJ**, Newcomb PA, Hampton JM, Trentham-Dietz A. Use of antidepressants and NSAIDs in relation to mortality in long-term breast cancer survivors. American Society for Preventive Oncology, Washington, DC, March 2010.
7. **Wernli KJ**, O'Meara ES, Kerlikowske K, Miglioretti D, Muller CY, Onega T, Sprague B, Yankaskas B, Cohen-Cline H, Buist DSM. Mammographic breast density and ovarian cancer. American Society for Preventive Oncology, Washington DC, March 2012.
8. Cohen-Cline H, **Wernli KJ**, Boles-Hall M, Bradford SC, Grossman D. IVR and Colorectal cancer screening adherence. Society for Epidemiologic Research, Minneapolis, MN, June 2012.
9. **Wernli KJ**, O'Meara E, Kerlikowske K, Miglioretti ML, Muller CY, Onega T, Sprague BL, Yankaskas B, Cohen-Cline H, Brandzel S, Buist DSM. Mammographic breast density and risk of incident ovarian cancer. 9th Biennial Ovarian Cancer Research Symposium presented by the Marsha Rivkin Center in Seattle, WA, September 2012.
10. Bowles, AJ, **Wernli KJ**, Gray HJ, Bogart A, Delate T, O'Keeffe-Rosetti M, Nekhlyudov L, Loggers, ET. Diffusion of intraperitoneal (IP) chemotherapy in women with ovarian cancer stage II or greater in the Cancer Research Network, 2003-2008. 9th Biennial Ovarian cancer Research Symposium, presented by the Marsha Rivkin Center in Seattle, WA, September 2012.
11. **Wernli KJ**, Rutter CM, Dachman AH, Zafar HM. Review of extracolonic findings by computed tomography colonography. International Cancer Screening Network, Sydney, Australia, October 2012.
12. **Wernli KJ**, Brenner AT, Rutter CM, Inadomi J. Short-term risks associated with sedation during colonoscopy: evaluation of the 2009 CMS mandate for anesthesia services. AcademyHealth, Baltimore, MD, June 2013.
13. **Wernli KJ**. Using qualitative methods to inform confounding: an example in breast imaging. Society for Epidemiology Research, Seattle, WA, June 2014.
14. Brandzel S, Rosenberg D, Bush M, Johnson D, Henderson L, Kerlikowske K, Onega T, DeMartini W, **Wernli KJ**. A Qualitative Examination of Patient Experiences and Preferences Regarding Surveillance Breast Imaging after Treatment for Breast Cancer. American Society of Preventive Oncology, Birmingham, AL, March 2015.
15. **Wernli KJ**, Hubbard R, Johnson E, Chubak J, Kamineni A, Rutter CM. Patterns of colorectal cancer screening uptake in men and women newly-eligible for screening. International Cancer Screening Network Conference, Rotterdam, The Netherlands, June 2015.
16. **Wernli KJ**, Kamineni A, Johnson E, Shortreed SM, Green BB, Chubak J, Rutter CM. Current patterns of colorectal cancer screening in an insured population. American Society for Preventive Oncology, Columbus, OH, March 2016.

17. **Wernli KJ** and Artefact. Designing for good patient decisions: bringing together data, psychology, and human-centered design to help breast cancer survivors chose a method for post-treatment surveillance. Stanford Medicine X, Palo Alto, CA, September 2016.
18. **Wernli KJ**, Ichikawa I, Kerlikowske K, Bush M, Johnson D, Buist DSM, Brandzel SD, DeMartini WB, Henderson L, Nekhlyudov L, Onega T, Sprague B, Miglioretti DL. Comparative performance of surveillance mammography and breast MRI in women with a history of breast cancer. The San Antonio Breast Cancer Symposium, San Antonio, TX, December 2016.
19. Gray M, Ludman EJ, Beatty TC, **Wernli KJ**. Using Twitter for recruitment, patient engagement, and data collection in a study about adolescent and young adults with late stage cancer. American Society for Preventive Oncology, Seattle, WA, March 2017.
20. Gray M, Ludman EJ, Beatty TC, **Wernli KJ**. Balancing hope and risk for adolescent and young adult cancer patients with late stage cancer. American Society for Preventive Oncology, Seattle, WA, March 2017.
21. Haas C, **Wernli KJ**, Phipps A, Hajat A, Kamenini A, Chubak J. Disparities in completion of fecal immunochemical tests for colorectal cancer screening in a health maintenance organization setting. American Society for Preventive Oncology, Seattle, WA, March 2017.
22. Gray M, Ludman EJ, Beatty TC, **Wernli KJ**. Using Twitter for recruitment, patient engagement, and data collection in a study about adolescent and young adults with late stage cancer. Pacific Northwest Palliative Care Conference, Seattle, WA, April 2017.
23. Gray M, Ludman EJ, Beatty TC, **Wernli KJ**. Balancing hope and risk for adolescent and young adult cancer patients with late stage cancer. Pacific Northwest Palliative Care Conference, Seattle, WA, April 2017.
24. Haas C, **Wernli KJ**, Phipps A, Hajat A, Kamenini A, Chubak J. Disparities in completion of fecal immunochemical tests for colorectal cancer screening in a health maintenance organization setting. Society for Epidemiologic Research, Seattle, WA, June 2017.

Invited Oral Presentations

Local

1. **Wernli KJ**. Ovarian and Endometrial Cancers in Textile Workers. Science over Lunch, Fred Hutchinson Cancer Research Center, May 2007.
2. **Wernli KJ**. Hormone Therapy and Cancer. Science over Lunch, Fred Hutchinson Cancer Research Center, April 2008.
3. **Wernli KJ**, Sethi R. Evaluation of patient outcomes for complex spine surgery 2008-2012. Group Health Research Institute Birnbaum Research Rounds, May 8, 2014.
4. **Wernli KJ**, Bush M, Johnson D. Success Patient-Research Collaboration. Keynote speakers for 2nd Annual CERTAIN Patient Advisory Board Network Annual Symposium. November 3, 2014.
5. **Wernli KJ**. Patient-centered approach to surveillance breast imaging: Lessons learned from SIMBA. Group Health Research Institute Seminar, Seattle, WA, July 27, 2016.

National

6. **Wernli KJ**. Medications, Multivitamins, and Breast Cancer Survival. American Society for Preventive Oncology, Tampa, FL, March 2009.
7. **Wernli KJ**. Patient-centered outcomes research: an example in surveillance breast imaging for breast cancer survivors. University of North Carolina, Chapel Hill: Cancer Outcomes Research Program, April 29, 2014.

8. **Wernli KJ** and Johnson D. Patient-Centered Outcomes Research Institute. Patient and Family Engagement Rubric. Stanford Medicine X, September 6, 2014.
9. Johnson D, Brandzel S, Bush M, **Wernli K**. Journey of a patient partner in research: an example in a PCORI funded project. Stanford Medicine X, Palo Alto, CA. September 27, 2015.
10. **Wernli KJ**. New Insights in Surveillance and Rehabilitation after Cancer and Stroke. 1st Annual PCORI Meeting, Washington DC, October 7, 2015.
11. **Wernli KJ**, Pfarr N. Informing breast cancer decisions with human-centered design. Innovative Learning Network. San Jose, CA, May 11, 2016.
12. **Wernli KJ**. Using qualitative methods to learn about confounders. Epidemiology Congress of the Americas, Miami, FL, June 24, 2016.
13. **Wernli KJ**. What is the current state of end of life in adolescent and young adult cancer patients across the US? Dana Farber Cancer Institute, Boston, MA, October 4, 2016.
14. **Wernli KJ**. Patient-centered approach to surveillance breast imaging: Lessons learned from SIMBA. Columbia University, New York City, NY, October 6, 2016.
15. **Wernli KJ**. What is the current state of end of life in adolescent and young adult cancer patients across the US? Pediatric Oncology Group Ontario, Toronto, Canada, October 7, 2016.
16. **Wernli KJ**, Bush M. Comparative effectiveness of surveillance breast imaging modalities in breast cancer survivors. In Pre-engagement in PCOR: Incorporating Lessons from the Field at Second annual Patient Centered Outcomes Research Institute meeting, National Harbor, MD, November 19, 2016.
17. **Wernli KJ**, Miglioretti D. Patient Engagement in oncology research. UC Davis Community Engagement, Sacramento, CA, November 13, 2017.

Plenary presentations

1. **Wernli KJ**, Johnson D. Plenary: Straight from the Source. Panel of patient and researcher teams at 1st Annual PCORI Meeting. October 7, 2015.
2. **Wernli KJ**, Brandzel S, Bush M, Johnson D. Models of Patient Engagement. INSPIRE Symposium, Seattle, WA, July 19, 2016.

Panels

1. Panel member at "PORP career paths by UW graduate panel" for Pharmaceutical Outcomes Research Program at University of Washington, May 3, 2013.
2. Panel member at 1st Annual CERTAIN Patient Advisory Board Network Annual Symposium. October 31, 2013.
3. Panel member at American Society for Preventive Oncology in Columbus OH. Strategies for building, prioritizing, and sustaining a research group: how to manage time and leverage available resources effectively. March 13, 2016.
4. Panel member at American Society for Preventive Oncology in Seattle, WA. A Roadmap to Academic and Research Environments: Identifying and Choosing the Best Fit for your Career Goals. March 12, 2017.

Invited Webinar presenter

1. Patient-centered Outcomes Research. Presented to Cancer Research Network Scholars, July 8, 2014.
2. Patient and Stakeholder Engagement in Research: Strategies for Initiating Research Partnerships. Invited by Patient-Centered Outcomes Research Institute, July 19, 2017.

TEACHING ACTIVITIES

2003	Teaching Assistant, Undergraduate Epidemiology course, Department of Epidemiology, University of Washington, Seattle WA
2005-2006	Teaching Assistant, Epidemiology and Biostatistics course, School of Medicine, University of Washington, Seattle WA
2008	Instructor, Epidemiology course, Seattle Midwifery School, Seattle WA
2011-2013	Guest lecturer, Graduate seminar, School of Social Work, University of Washington, Seattle WA
2014	Guest lecturer, HSERV 592K Graduate Student Seminar, Department of Health Services, University of Washington, Seattle WA. January 2014 Guest lecture, PHARM 597 Graduate Student Seminar, Department of Pharmaceutical Outcomes Research Program, University of Washington, Seattle WA. December 2014.
2015	Guest lecture, EPI 583 Graduate Student Seminar, Department of Epidemiology, University of Washington, Seattle, WA. April 2015
2016	Preceptor, EPI 514 Applications in Epidemiologic Methods, Department of Epidemiology, University of Washington, Seattle, WA. Spring 2016 Seminar speaker, University of Washington, Surgical Outcomes Research Center (SORCE) Fellows Methods seminar, Seattle, WA, December 2016

THESIS COMMITTEES

Master's thesis

Cameron Haas (Member), 2015-2017
Sharon Hwee (Chair), 2016-

ADVISING & FORMAL MENTORING

Mentored scientists and post-docs

Josh Roth, PhD, Assistant Member and K12 Scholar, Fred Hutchinson Cancer Research Center, serve as mentor, 2014-2016

Carrie Bennette, Post-doctoral Fellow and K12 Scholar, University of Washington, serve as a mentor, 2015-2016

Sara Javid, MD, Associate Professor, Department of Surgery, University of Washington, serve as CRN mentor member, 2015-2016

Sarah Knerr, PhD, Post-doctoral Fellow at Group Health Research Institute and Assistant Investigator and K12 Fellow at University of Washington, serve as mentor, 2015-present

Marlaine Gray, PhD, Research Associate, Group Health Research Institute, serve as mentor, 2015 – present

Zachary Marcum, PhD, Assistant Professor and K12 Scholar, University of Washington, serve a mentor, 2016-present.

Master's students

Hannah Cohen-Cline, MPH student, served as primary mentor, 2010-2012

Cameron Haas, MPH Student, Department of Epidemiology, University of Washington, serve as mentor, 2015-present

Sharon Hwee, MS Student, Department of Health Services, University of Washington, serve as mentor, 2017-present

Undergraduate students

Danielle Olmstead, Undergraduate Group Health Student Intern, served as primary mentor, 2012-2013

Sandra Hwang, Undergraduate Group Health Student Intern, served as primary mentor, 2013

MEDIA COVERAGE

1. Patterns of breast magnetic resonance imaging use in community practice

- [JAMA] (2014, November 18). Patterns of breast MRI use in practice. [Video file]. Retrieved from: [The JAMA Network](#)
- Alliance of Community Health Plans (ACHP), Nov 18, 2013 [High-risk women get breast MRI—but room remains for improvement](#)
- Daily Rx, Nov 18, 2013 [Why breast MRI is increasing](#)
- Healthday (syndicated in [Philadelphia Inquirer](#), [US National Library of Medicine](#), [Oncology Nurse Advisor](#), etc.), Nov 18, 2013 [Use of breast MRIs way up, studies find](#)
- Medical Xpress, Nov 18, 2013 [Two new studies on the use of breast MRI](#)
- Medpage Today, Nov 18, 2013 [Breast MRI use up despite lack of indications](#)
- Modern Healthcare, Nov 18, 2013 [Breast MRI use up, but not enough among the right patients](#)
- Aunt Minnie, Nov 19, 2013 [Breast MRI use grows, but does it benefit the right women?](#)
- Live Science (syndicated in [Fox News](#), etc.) Nov 19, 2013 [Breast MRIs not always used appropriately, studies suggest](#)
- Reuters (syndicated in [Chicago Tribune](#), [Yahoo](#), etc.), Nov 19, 2013 [Breast MRI use increasing among U.S. women](#)
- DOTmed News, Nov 20, 2013 [Use of breast MRI increased, says study](#)
- The ASCO Post, Nov 25, 2013 [Further improvement needed in breast MRI use in community practice](#)

2. Patient and stakeholder engagement

- Group Health Research Institute Blog: Ridpath, J (2014, April 3). [‘Glad you’re listening’: SIMBA study brings patients’ voices to the fore](#)
- Dockser Marcus, A. ["Design Power: Patients Play Researchers in Drug Trials."](#) September 29, 2014.
- Group Health Research Institute Blog: Ridpath J (2014, October 3). [Wall Street Journal shines light on our patient researchers](#)
- CERTAIN Blog: Lawrence, S. (2014, December 5). [Research Partners Spotlight: Karen Wernli, Mary Bush, and Dianne Johnson.](#)
- Group Health Research Institute Blog: (2016, February 10). [Patients power SIMBA research on breast cancer, mammograms and breast MRIs](#)
- [Group Health Research Institute] (2016, February 16). *Making Medicine Better By Working Together.* [Video File]. Retrieved from https://youtube/llsYo_pqyZQ
- Anyanwu C and Hemphill R. [Finding and recruiting research partners; lessons from PCORI awardees.](#) September 1, 2017.

3. Short-term risks associated with general anesthesia during colonoscopy compared to conscious sedation in US adult population

- Group Health Research Institute Blog: Wernli, KJ. (2015 Dec 22). [Deep sedation raises risk of complications from colonoscopy](#)

- *American Gastroenterological Association*, Jan 26, 2016. [Colonoscopy risk increases with anesthesia](#)
- [GI & Hepatology News] (2016, March 31). Risks associated with anesthesia services during colonoscopy. [Video file]. Retrieved from: <https://www.youtube.com/watch?v=k41P0QUGUpo>
- *A Woman's Health*, Apr 7, 2015. [Anesthesia increases colonoscopy risks.](#)
- *Healio Gastroenterology*, Mar 30, 2016. Risk for complications after colonoscopy increase

4. Lung cancer screening

- Group Health Research Institute Blog: Nazarko J. (01/08/2016). [Group Health's new lung cancer screening program shows promise](#)
- Group Health Research Institute Blog: Brandzel (03/11/2016). [Patients and providers talk about lung cancer screening, GHRI listens](#)

5. End of life care in adolescent and young adult cancer patients

- Group Health Research Institute Blog, Wernli KJ (05/16/2016)). [For young adults with cancer, the Clare Project asks: what matters most.](#)
- Pallimed: A Hospice & Palliative Medicine Blog (06/29/2016): [The Clare Project and "What Matters most?" to young people with advanced cancer.](#)

6. Breast cancer surveillance imaging

- FastCo Design. Wilson, M (6/22/16). [Post-cancer checkups are stressful – this decision aid is designed to help.](#)
- Artefact (6/20/2016). [SIMBA Decision Aid.](#)
- Patient-Centered Outcomes Research Institute Blog (10/3/16). [Helping survivors of breast cancer watch out for recurrences.](#)
- [Patient Centered Outcomes Research Institute] (2016 October 3). Helping breast cancer survivors watch out for recurrences. [Video file]. Retrieved from <http://www.pcori.org/blog/helping-survivors-breast-cancer-watch-out-recurrences>
- KP Washington Health Research Institute (2/28/17). [Patient-researcher helps advance care for other breast cancer survivors.](#)
- KP Washington Health Research Institute (3/10/17). [Breast cancer screening choice made easier by research-design team.](#)

LANGUAGES

English – native language

German and Spanish – speak, read, and write with basic competence.